Research chemicalPsychedelicTryptamineSerotonergic5-Methoxytryptamine
5-MeO-pyr-T (5-Methoxy-pyrrolidyltryptamine)
Also known as 5-Methoxy-pyrrolidyltryptamine · 5-MeO-pyrT
5-MeO-pyr-T is a 5-methoxytryptamine in which the terminal nitrogen is part of a pyrrolidine ring. Documented in Shulgin's TIHKAL as active, it is a rare psychedelic research chemical with minimal human data.
01 Overview
5-MeO-pyr-T (5-methoxypyrrolidyltryptamine) was characterised by Alexander Shulgin, who noted psychoactivity. The pyrrolidine ring locks the amine into a cyclic structure, distinguishing it from open-chain 5-methoxytryptamines.
Outside of Shulgin's self-experiments there is essentially no data. Dosing and effects below are drawn from that limited source and should be considered anecdotal.
02 Mechanism
Serotonin receptor agonist with 5-HT2A/5-HT1A activity typical of 5-methoxytryptamines.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common (Shulgin range) | 0.5–2 mg | Oral | Very potent per TIHKAL; anecdotal. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Psychedelic threshold effectsPerceptual and cognitive changes reported at low milligram doses. | mild-moderate | Anecdotal | |
| Altered body sensationPhysical effects described by Shulgin. | variable | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Cardiovascular stimulationRaised heart rate/blood pressure common to 5-methoxytryptamines. | Moderate | Common | Anecdotal | |
| AnxietyUnease at higher doses; potency makes overdosing easy. | Moderate | Common | Anecdotal |
06 Legal status
United Kingdom
Class A (tryptamine generic clause)
as of Jan 2026
United States
Possibly Analogue Act
as of Jan 2026
07 References
Shulgin A, Shulgin A. TIHKAL: The Continuation (5-MeO-pyr-T entry)Transform Press, 1997
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.